RTP Mobile Logo

Regional Meetings 2018

Investigator Perspectives on Current Clinical Issues and Ongoing Research Shaping the Management of Follicular Lymphoma — An Interactive Grand Rounds Series

Research To Practice (RTP) is pleased to offer community- and academic-based hospitals and cancer centers throughout the United States the opportunity to participate in an interactive live educational activity focused on the management of follicular lymphoma. Each session in this regional series will feature a blend of didactic presentation, interactive polling of attendees using keypad devices and follow-up audience Q&A.

If you are interested in hosting a session at your institution, please contact our Meeting Services Department at Meetings@ResearchToPractice.com or call (800) 233-6153.

Learn about our other CME series Visiting Professors: Investigator Perspectives on the Management of Soft Tissue Sarcoma and Novel and Emerging Therapeutic Strategies in the Management of Non-Small Cell Lung Cancer.

Event Details

Schedule of Events:

Meetings to be announced

There is no registration fee for these events. However, preregistration is advised as seating is limited.

Agenda

Each 1-hour will include 3 topic modules focused on current management, emerging research and novel agents and strategies under active investigation for follicular lymphoma (FL). Each event will employ an identical format that will include the following elements:

  • Steering Committee Responses to Related Clinical Questions
  • Key Clinical Research Findings
  • Audience Polling
MODULE 1 Optimizing the Care of Patients with Newly Diagnosed FL MODULE 2 Biologic Rationale for and Current Clinical Role of Maintenance Therapy in FL MODULE 3 Management of Relapsed/Refractory FL

Each session will conclude with a 5-minute Q&A segment

STEERING COMMITTEE MEMBERS

Bruce D Cheson, MD
Professor of Medicine
Deputy Chief, Division of Hematology-Oncology
Head of Hematology
Georgetown University Hospital
Lombardi Comprehensive Cancer Center
Washington, DC

Andrew M Evens, DO, MSc
Associate Director for Clinical Services
Rutgers Cancer Institute of New Jersey
Medical Director, Oncology Service Line
RWJBarnabas Health
Director, Lymphoma Program
Division of Blood Disorders
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey

Christopher Flowers, MD, MS
Associate Professor of Hematology and Medical Oncology
Emory School of Medicine Winship Cancer Institute
Atlanta, Georgia

Nathan H Fowler, MD
Co-Director of Clinical and Translational Research
Lead, Phase I and Indolent Research Groups
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Ann S LaCasce, MD, MMSc
Program Director, Fellowship in Hematology/Oncology
Associate Professor of Medicine, Harvard Medical School
Institute Physician
Lymphoma Program
Dana-Farber Cancer Institute
Boston, Massachusetts

John P Leonard, MD
Richard T Silver Distinguished Professor of Hematology and Medical Oncology
Associate Dean for Clinical Research
Weill Cornell Medical College
New York, New York

Julie M Vose, MD, MBA
Neumann M and Mildred E Harris Professor
Chief, Division of Hematology/Oncology
Nebraska Medical Center
Omaha, Nebraska

Andrew D Zelenetz, MD, PhD
Medical Director, Medical Informatics
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

 

CE Information

Target Audience:
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of follicular lymphoma (FL).

Learning Objectives:

  • Compare and contrast the self-reported practice patterns of lymphoma clinical investigators, and apply this knowledge to the diagnosis and treatment of FL.
  • Recognize published research data and recent FDA authorizations when designing an optimal induction therapeutic approach for patients with newly diagnosed FL requiring active therapy.
  • Appreciate emerging Phase III data with the use of rituximab/lenalidomide as front-line treatment for FL, and optimally incorporate this novel therapeutic approach into current management algorithms.
  • Individualize the use of maintenance therapeutic approaches in the management of newly diagnosed FL.
  • Consider published research data and other clinical factors in the best-practice selection, sequencing or combining of available therapeutic agents in the nonresearch care of patients with relapsed/refractory FL.
  • Develop practical strategies to prevent, recognize and ameliorate the toxicities associated with therapies routinely used in the management of FL.
  • Identify ongoing clinical trials evaluating innovative investigational approaches for FL, and obtain consent from appropriate patients for study participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Commercial Support:
These activities are supported by educational grants from Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech and Gilead Sciences Inc.